NCT00323544已完成3 期
A Phase 3, Open Label, Randomised, Parallel Group Study to Compare the Effect on Prevention and Resolution of Treatment Related Adverse Events of a Simplified, Once Daily Regimen of a Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Twice Daily co-Formulated Zidovudine and Lamivudine (Combivir®) or Zidovudine and Lamivudine, in Virologically Suppressed, HIV Infected Patients Taking Efavirenz
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 220
- 试验地点
- 2
- 主要终点
- The primary endpoint for the study is a change from baseline in absolute haemoglobin at Week 24.
研究概览
简要总结
This study will investigate whether the simplified regimen of a once daily fixed dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate [DF]) will be associated with a reduced rate of adverse events, seen with long term use of antiretrovirals, as well as improved adherence compared to a twice daily fixed dose combination of Combivir.
详细描述
The success of HAART is largely dependant on an individual's ability to adhere strictly to an antiretroviral regimen. Regimen characteristics that affect adherence include dosing frequency and pill burden. Several studies have shown improved adherence with lower pill burden and a meta-analysis of the virological outcome in relation to pill burden has shown a significant correlation between lower pill burden and better virological outcome. A systematic review of studies across a range of medical specialties demonstrated that once daily therapy improves adherence relative to more frequent dosing although statistical significance was not demonstrated relative to twice daily regimens.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of either sex aged > 18 years.
- •HIV positive.
- •Stable antiretroviral therapy consisting of efavirenz (EFV) given with Combivir® or zidovudine (AZT) + lamivudine (3TC) for at least 6 months.
- •Patients with viral loads < 50 copies/ml on last 2 consecutive tests and < 400 copies/ml for > 3 months.
- •Patients requiring a lipid lowering agent must be established on a stable dose/frequency for at least 12 weeks prior to Baseline and be expected to continue on stable dose/frequency for the duration of the study.
- •Negative serum pregnancy test (females of childbearing potential only).
- •Willingness to use effective contraception (such as barrier or coil methods) by both males and females while on study treatment and for 30 days following study drug completion.
- •The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
排除标准
- •Pregnant or lactating female.
- •History of AZT monotherapy.
- •Use of anabolic steroids, with the exception of testosterone for documented hypogonadism, within 90 days prior to the Baseline visit.
- •Documented parvovirus infection.
- •Use of erythropoietin within the last six weeks.
- •Patients who have had a blood transfusion in the last six weeks.
- •Karnofsky score <
- •Prior history of significant renal disease.
- •Prior history of osteopenia/osteoporosis.
- •Creatinine clearance < 60mL/min.
- •AST/ALT > 5 x upper limits of normal (ULN).
- •Previous adefovir dipivoxil or cidofovir therapy.
- •Known history of resistance (including primary resistance) to any of the study medications - tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), AZT, 3TC, or EFV.
- •Patients receiving ongoing therapy with any of the following (administration of any of the following medications must be discontinued at least 30 days prior to the Baseline visit and for the duration of the study period):
- •Nephrotoxic agents
- •Probenecid
- •Systemic chemotherapeutic agents (i.e. cancer treatment medications)
- •Systemic corticosteroids
- •Interleukin 2 (IL 2)
- •Drugs that interact with efavirenz
- •Dihydroergotamine
- •Ergotamine
- •Midazolam
- •Triazolam
- •Cisapride
- •Ergonovine
- •Methylergonovine
- •Patients with known hypersensitivity to any of the study medications or excipients.
- •Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic therapy within 15 days prior to Screening.
- •Patients who are currently taking part in any other clinical trial or have taken part in a clinical trial of a new chemical entity within 1 month prior to Screening.
- •Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the dosing requirements.
- •Patients with cancer (except basal cell carcinoma).
- •Co-infection with hepatitis B virus
结局指标
主要结局
The primary endpoint for the study is a change from baseline in absolute haemoglobin at Week 24.
次要结局
- The secondary endpoints in this study include: Change from baseline in absolute haemoglobin at Week 48
- Lipids profile: change from baseline in total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL), TC/HDL, and triglyceride (TG)
- Quality of life (QoL)
- Measures of treatment adherence (Medication Adherence Self-Report Survey [MASRI] questionnaire)
- Measures of regimen intrusiveness (HIS and Brief Medication Questionnaire [BMQ])
- Changes in markers of body composition from dual energy x-ray absorptiometry (DEXA) scans (a sub-study)
- HIV RNA: proportion of patients with HIV ribonucleic acid (RNA) < 400 copies/mL; proportion of patients with HIV RNA < 50 copies/mL and change from baseline in log10 copies/mL at Weeks 24 and 48
- CD4: change from baseline in CD4 counts
- Treatment adherence and acceptability
- Use of lipid lowering drugs (number of patients and duration of use)
- Adverse events (AEs): AEs will be coded and the coded terms will be used to summarize the count of patients with any event, intensity of each event (highest intensity will be used if an event is reported more than once by a patient) and relationship to:
- Other lab tests: results at baseline and changes from baseline
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil AloneEssential HypertensionNCT01456169Takeda507
已完成
3 期
A Study of Monthly Risedronate for OsteoporosisPostmenopausal OsteoporosisNCT00247273Warner Chilcott1,294
已完成
3 期
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced PatientsInfection, Human Immunodeficiency Virus IHIV InfectionNCT00046176ViiV Healthcare240
已完成
3 期
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsHIV-1 InfectionNCT02607930Gilead Sciences631
已完成
3 期
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsHIV-1 InfectionNCT02607956Gilead Sciences657